FindTrial
Sign In

The establishment and clinical application of a method for monitoring the concentration of anti-tuberculosis drugs in saliva

The establishment and clinical application of a method for monitoring the concentration of anti-tuberculosis drugs in saliva

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500099601
Enrollment
Unknown
Registered
2025-03-26
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

Trial group:NO

Sponsors

Beijing Chest Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily agree to be a subject, sign an informed consent form; 2. Age between 18-65 years, male or female; 3. Refer to the diagnostic criteria for pulmonary tuberculosis in the WS 288—2017 "Pulmonary Tuberculosis Diagnostic Criteria"; 4. Have been taking anti-tuberculosis drugs stably for more than 1 week.

Exclusion criteria

Exclusion criteria: 1. Immunocompromised individuals (such as diabetes, AIDS, systemic lupus erythematosus); 2. Pregnant and lactating women; 3. Inappropriate samples for testing (such as insufficient volume of isolated samples or inadequate treatment).

Design outcomes

Primary

MeasureTime frame
Plasma drug concentration;Saliva drug concentration;—

Countries

China

Contacts

Public ContactHuang Hairong

Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China

huanghairong@tb123.org+86 136 9916 5450

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026